The proposed Mayo Alzheimer's Disease Research Center (ADRC) will build upon the experience of the previously funded Mayo Alzheimer's Disease Center (P30) and the new faculty at Mayo Jacksonville, FL and the Mayo Scottsdale, AZ to address research questions in aging and Alzheimer's disease (AD). The ADRC will consist of five cores: Administrative Core, Clinical and Research Support Core, Neuropathology and Genetics Core, Neuroimaging Core and Education and Information Transfer Core, and two projects: Project 1: """"""""Cytoskeletal Pathology in the Neurodegeneration of AD,""""""""Project """"""""The contribution of Leukoaraisosis to Cognitive Impairment in Aging and Alzheimer's Disease."""""""" The Center will address several scientific themes including neuroepidemiology of dementia and AD, the boundary between normal aging and AD, and predictors of cognitive impairment in asymptomatic persons. New faculty appointments in Mayo Jacksonville in the basic science of amyloid processing, tau, genetics and antibody development will complement the clinical and epidemiology expertise in the remainder of the Center. Investigators in Scottsdale will add functional imaging studies in at-risk subjects to pursue the scientific themes of the Center. The proposed ADRC will extend the productivity of the existing Alzheimer's Disease Center and develop new insights into aging and AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG016574-02S2
Application #
6092881
Study Section
National Institute on Aging Initial Review Group (NIA)
Program Officer
Phelps, Creighton H
Project Start
1999-05-01
Project End
2004-04-30
Budget Start
2000-06-01
Budget End
2001-04-30
Support Year
2
Fiscal Year
2000
Total Cost
$181,712
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Jones, David T; Knopman, David S; Graff-Radford, Jonathan et al. (2018) In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology 90:e947-e954
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Wennberg, Alexandra M V; Lesnick, Timothy G; Schwarz, Christopher G et al. (2018) Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 73:1244-1250
Wennberg, Alexandra M V; Hagen, Clinton E; Edwards, Kelly et al. (2018) Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. Int J Geriatr Psychiatry 33:1114-1120
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Sahoo, Aradhana; Bejanin, Alexandre; Murray, Melissa E et al. (2018) TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia. J Alzheimers Dis 64:1227-1233

Showing the most recent 10 out of 1014 publications